WS13.5 Development of a LC-MS/MS method for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO
Schneider, E.K, Reyes-Ortega, F, Wilson, J, Kotsimbos, T, Keating, D, Velkov, T, Li, J
Published in Journal of cystic fibrosis (01.06.2017)
Published in Journal of cystic fibrosis (01.06.2017)
Get full text
Journal Article
WS01.3 A ‘surprising’ pair: the synergistic antimicrobial activity of polymyxin B in combination with the cystic fibrosis drug ivacaftor against polymyxin-resistant P. aeruginosa
Schneider, E.K, Azad, M.A.K, Zhou, Q.T, Wang, J, Huang, J.X, Cooper, M.A, Doi, Y, Muller, M.T, Li, J, Velkov, T
Published in Journal of cystic fibrosis (01.06.2016)
Published in Journal of cystic fibrosis (01.06.2016)
Get full text
Journal Article
ePS6.07 Synergistic killing of polymyxin B in combination with the CFTR potentiator ivacaftor against polymyxin-resistant Pseudomonas aeruginosa isolates from the cystic fibrosis paediatric lung: an untargeted metabolomics study
Hussein, M., Li, J., Velkov, T., Schneider-Futschik, E.K.
Published in Journal of cystic fibrosis (01.06.2019)
Published in Journal of cystic fibrosis (01.06.2019)
Get full text
Journal Article